Radicle Science, an AI-driven healthtech B-corp company reported strong positive results from one of the largest clinical trials on pain treated with cannabinoids. The study involved over 1,600 participants from across the U.S. It was a randomized and controlled clinical trial done in partnership with Open Book Extracts (OBX). All the formulations in the trial led to statistically significant and clinically meaningful improvements in pain after just 4 weeks—all with minimal side effects.
The companies said it was the first of its kind to examine the synergistic impact of rare cannabinoids like Cannabichromene (CBC) and Cannabigerol (CBG) on pain. All formulations in the pain study on Cannabidiol (CBD) and Rare Cannabinoids were supplied by OBX, which is a NSF-certified manufacturer and distributor of cannabinoid ingredients and finished products.
“We at OBX are fundamentally dedicated to supporting all consumers in their endeavor to feel their best from the inside out through a holistic universe of effective, evidence-based cannabinoid products of the highest quality,” said OBX CEO Dave Neundorfer. “While existing studies suggest that cannabidiol and rare cannabinoids, including CBG and CBC, have considerable potential to support wellness, there has been a glaring gap in scientifically valid research dedicated to guiding effective product development. That’s why we collaborated with the renowned medical experts and data scientists at Radicle Science to better understand the potential of rare cannabinoids as an ingredient and, in particular, their ability to support better quality of life outcomes relating to pain.”
The study found that on average, nearly half (44.8%) of participants who received any of the enhanced products experienced a clinically meaningful improvement in their pain, meaning they realized a distinct and palpable improvement in their quality of life through improved pain symptoms.
Overall, the different enhanced formulations performed roughly the same for the improvement of pain, anxiety, sleep quality, and quality of life. However, for people with moderate pain, there was evidence that the addition of 20mg CBC to a formulation containing 40mg of CBD could significantly improve its pain-relieving effects—particularly when this enhanced product was taken for 2 or more weeks. All products tested were deemed safe to consume. Only about 1 in 10 participants reported side effects, and none were severe.
“It’s a privilege to make history with OBX,” said Dr. Jeff Chen, MD, Radicle Science’s CEO and UCLA Cannabis Research Initiative’s founder and former Executive Director. “Rare cannabinoids are present in a variety of health and wellness products containing cannabis and hemp, but there has been virtually no clinical data on their effectiveness for any medical condition, including pain. Radicle Science assessed for the first time in history the potential synergistic effects of certain rare cannabinoids on pain and demonstrated that these natural products can make a measurable positive impact.”
Pelin Thorogood, Radicle Science Co-founder and Executive Chair added, “It was promising to see that the addition of a rare cannabinoid could augment the effects of CBD. We will be further exploring the entourage effect with an upcoming study, Radicle Spectrum, which will be the first head-to-head study comparing full or broad spectrum CBD to isolate and placebo. It is our hope this study will provide data to help the FDA ascertain whether CBD isolate is a drug.”